Amelioration of junctional epidermolysis bullosa due to exon skipping
- 6 March 2016
- journal article
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 174 (6) , 1375-1379
Abstract
Mutations in the COL17A1 gene lead to the genetic blistering disorder junctional epidermolysis bullosa generalized intermediate type (JEB-gen-intermed). Antisense oligonucleotide-mediated exon skipping is a strategy that aims to skip the mutation-containing exon and thereby produce a smaller but functional protein. COL17A1 is an interesting candidate, as 53 of the 55 exons (96%) can be skipped without disturbing the reading frame. Information on the functionality of the shortened protein product is important in order to obtain support for this therapeutic strategy. Here we report a patient with JEB-gen-intermed with amelioration of the phenotype due to exon 49 skipping by two distinct mechanisms - premature termination codon-induced exon skipping and revertant mosaicism - both of which induced skipping of the same exon. The patient was compound heterozygous for two inherited COL17A1 mutations, a frameshift mutation in exon 18 (c.1490_1491delinsT, p.Ala497Valfs*23) and a nonsense mutation in exon 49 (c.3487G>T, p.Glu1163Ter). Upon clinical examination, skin patches were found that were resistant to blister formation. In these patches, naturally corrected cells were present that harboured an additional splice-site mutation, c.3419-1G>T, resulting in skipping of the mutation-containing exon 49. This natural gene therapy phenomenon shows that type XVII collagen with residues 1140-1169 deleted is largely functional. In addition, in affected skin cells a low level of exon 49 skipping was observed. Our results support the notion that skipping of a mutated in-frame exon in COL17A1 ameliorates the phenotype.Keywords
Funding Information
- Priority Medicines Rare Diseases (E-RARE) grant SpliceEB
- The Dutch Butterfly Child Foundation
This publication has 13 references indexed in Scilit:
- Mechanisms of Natural Gene Therapy in Dystrophic Epidermolysis BullosaJournal of Investigative Dermatology, 2014
- Inherited epidermolysis bullosa: Updated recommendations on diagnosis and classificationJournal of the American Academy of Dermatology, 2014
- Analysis of Cutaneous Somatic Mosaicism2012
- Antisense-Mediated Exon Skipping to Reframe Transcripts2012
- A founder synonymous COL7A1 mutation in three Danish families with dominant dystrophic epidermolysis bullosa pruriginosa identifies exonic regulatory sequences required for exon 87 splicingBritish Journal of Dermatology, 2011
- Systemic Administration of PRO051 in Duchenne's Muscular DystrophyNew England Journal of Medicine, 2011
- Molecular mechanisms of phenotypic variability in junctional epidermolysis bullosaJournal of Medical Genetics, 2011
- Targeted Skipping of a Single Exon Harboring a Premature Termination Codon Mutation: Implications and Potential for Gene Correction Therapy for Selective Dystrophic Epidermolysis Bullosa PatientsJournal of Investigative Dermatology, 2006
- Characterization of the Anti-BP180 Autoantibody Reactivity Profile and Epitope Mapping in Bullous Pemphigoid Patients11Tables 1, 2, 3 and 5 can be found at http://www.blackwellpublishing.com/products/journals/suppmat/jid/jid22126/jid22126sm.htmJournal of Investigative Dermatology, 2004
- A Homozygous Nonsense Mutation in Type XVII Collagen Gene (COL17A1) Uncovers an Alternatively Spliced mRNA Accounting for an Unusually Mild Form of Non-Herlitz Junctional Epidermolysis BullosaJournal of Investigative Dermatology, 2001